Figure 3. Validation of prognostic model in other independent cohorts. (A) Distributions of ARGRS, survival status of NSCLC patients, and expression profiles of the gene signatures in the GSE30219 cohort. (B) Survival analysis showing the prognostic value of ARGRS in the GSE30219 cohort. (C) Comparison of ARGRS among different clinicopathologic features. (D, E) Survival analysis showing the prognostic value of ARGRS in the (D) GSE37745 and (E) GSE3141 cohort.